The latest price of venetoclax/venetoclax tablets after reimbursement in 2024

Venetoclax/Venetoclax (Venetoclax) is an oral targeted drug mainly used to treat certain types of hematological malignancies, especially chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Its main mechanism of action is to selectively inhibit Bcl-2 protein, an anti-apoptotic protein highly expressed in a variety of malignant tumor cells. By inhibiting Bcl-2, venetoclax can promote apoptosis in leukemia cells, thereby reducing the survival of cancer cells.

In recent years, the use of venetoclax has gradually been promoted in China, especially in the treatment of patients who are insensitive to traditional chemotherapy or who have relapsed. In the treatment of chronic lymphocytic leukemia, venetoclax is often used in combination with other drugs to enhance efficacy and improve patient survival rates. At the same time, for patients with acute myeloid leukemia, the application of venetoclax also brings new treatment options for this disease, especially those who carry specific gene mutations.

Regarding reimbursement, Venetexa has been included in China's Class B medical insurance, but the reimbursement policy is relatively strict and is limited to eligible adult acute myeloid leukemia patients. The reimbursement amount and reimbursement ratio of Venacla in medical insurance may be adjusted, and the specific situation needs to be determined according to the policies of the local medical insurance department.

As for the market price of venetoclax, the price in China usually varies according to different specifications. Common specifications include10mg, 50mg, 100mg, etc. The price of each box generally ranges from RMB 1,000 to RMB 4,000. After reimbursement, the patient's out-of-pocket expenses will be greatly reduced. For patients with heavy financial burdens, medical insurance coverage will undoubtedly provide great help.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto